Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease - Test2 - elhamkhani - TriplyDB

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

http://www.wikidata.org/entity/Q34526181

about

Family History of Alzheimer's Disease is Associated with Impaired Perceptual Discrimination of Novel Objects.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Tau PET imaging: present and future directions.Neuronal Cell Death and Degeneration through Increased Nitroxidative Stress and Tau Phosphorylation in HIV-1 Transgenic Rats.Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.Metabolic relationship between diabetes and Alzheimer's Disease affected by Cyclo(His-Pro) plus zinc treatment.Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study Whole Genome Expression Analysis in a Mouse Model of Tauopathy Identifies MECP2 as a Possible Regulator of Tau Pathology.PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure.History and future technical innovation in positron emission tomography.Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.P450 Eicosanoids and Reactive Oxygen Species Interplay in Brain Injury and Neuroprotection.Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease Defining imaging biomarker cut points for brain aging and Alzheimer's disease.Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition.Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials.Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease.AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease.18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum.Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy.The CNS in inbred transgenic models of 4-repeat Tauopathy develops consistent tau seeding capacity yet focal and diverse patterns of protein deposition.Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies Entorhinal Cortex: Antemortem Cortical Thickness and Postmortem Neurofibrillary Tangles and Amyloid Pathology.Alzheimer's drug-development pipeline: 2016.Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case The emerging role of PET imaging in dementia.Imaging of glia activation in people with primary lateral sclerosis.Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival only in APOE4-positive Alzheimer's disease.Entorhinal tau pathology, episodic memory decline and neurodegeneration in aging.Alzheimer's disease disrupts alpha and beta-band resting-state oscillatory network connectivity.

P2860

Q33556053-7C7E2121-0E5D-4870-A1FE-238A1958CA1A Q33556068-97E5E6F8-2EE7-459A-B1FF-ABAC5B1C26A4 Q34680852-D1E5E176-13A9-45C6-9BD4-7CCF0225ACC2 Q36255465-334C783B-326D-48C3-B7BF-14F4CDC678B0 Q37410164-59F0A919-1985-4789-9C19-F76A446DC185 Q37511619-66813DD3-C1C8-49A6-88E1-3E29710A5856 Q37569276-D4BD5F42-8CFC-4AC1-AC50-32089792F76A Q37600680-81DC6C6C-E372-4612-AF5B-4A679F7458D3 Q37707241-C16AC62A-2E0C-4F9B-BDE5-ED5DC37713C8 Q37718557-584F2CC1-FC5C-4FDA-8357-9428D9E31FBC Q37731919-B08283F3-A42A-42F2-9E9A-BDD5B6C80290 Q37739881-96CE8502-7C89-4381-82BD-975AD9A48DD7 Q38628805-F36103B3-5FB0-4F4C-A9BE-36BF72A3E216 Q38653494-93A4595C-F3AA-4907-B3ED-906957C28298 Q38731565-0FF62304-AC00-48AB-BE50-2EC0803687BE Q38739937-03878FD0-03BE-4CD2-A083-A1EED0B877AE Q38744600-681CD417-06E2-413C-86B0-0FE9A037013F Q38760663-4D1958B0-2732-47C9-9B83-5BE706FE7E07 Q38803637-362BE8AD-79EA-4F95-8585-885D9AF1EB4E Q38812890-554EB7A0-C6C2-4238-8B39-6EB2CFFE6687 Q38979999-1F1BCAA0-B527-493A-91D9-8F12F2648F9B Q38990773-AEEC7921-8B59-48FD-8CDD-DBE654B6137C Q39016306-BCE11EF4-0D3B-4759-ADF9-5046238ACF2A Q39451605-9BDEA770-5A65-4778-ABDF-7F1F1451F4B5 Q40239437-98129C11-BA64-45A5-B06F-F6217BCA2539 Q41496810-A079DB72-7AF9-4456-85BF-09F0A001B532 Q41600997-001D0634-BA95-40BA-A673-5784330BAE1E Q41654319-AC9D313B-2F4D-4EE2-A244-2C5CD712E3B2 Q41695282-C02B072B-4116-4CBC-A0D8-B61E79E9EA89 Q42279018-2264C486-B07A-4A91-B9EC-07AE4726A1C5 Q42371467-666407CA-AFCA-4662-82B8-CBF48DA8FD24 Q42619991-65F5C544-59E7-4F26-A529-1C701CF46978 Q42656263-E71CD644-2060-4A38-87C3-1661E0ACE98C Q42672461-D51AD0C5-E5ED-451D-A966-315274FF13CB Q42701971-FBF2311C-08FE-46F5-80F8-01CAD3034DF3 Q44728742-2EB2D8A8-2EF3-410D-8894-0C522975FF76 Q45974423-74E27ED6-705E-4525-AA73-11072982CB92 Q46003126-79CD483F-9021-4A7E-A74F-AEB73E3D1DBC Q46075858-67E1F618-6F13-44DB-92AF-0549E6F5A704 Q46323013-36C4E207-9DF8-46E7-AF6A-B2A77D5B4C0F

P2860

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

http://www.wikidata.org/entity/Q34526181

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

@ast

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

@en

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

@nl

type

label

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

@ast

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

@en

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

@nl

prefLabel

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

@ast

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

@en

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

@nl

P1433

Q34526181-F5B325DB-0F88-42A3-89FC-C5EEBEC73ECA

P1476

Q34526181-4959817B-859C-4D74-B675-C60522859B28

P2093

Q34526181-138BE666-DFE0-4A13-8B8F-7977EAB68E54

Q34526181-1B271028-D8E4-4067-BA64-B6D296B9C599

Q34526181-2695A9DA-AA73-41AC-B180-1E092AF83C17

Q34526181-5B2E532E-7238-4CE6-B51B-781A9E221A32

Q34526181-620BD36B-BF9B-4474-8E73-C750A94B978E

Q34526181-62CD3F4F-42EF-4790-9DFA-07296D954810

Q34526181-73F38082-B119-4A24-A9C4-8277CA3818D0

Q34526181-85E37CB3-582C-4CA4-A236-83BAB4DFF13F

Q34526181-94832F9F-26C0-48F8-9900-7A4EB9FFCB81

Q34526181-AF45296B-D22F-41EB-890D-904E667E423F

P2860

Q34526181-0451112F-7D92-40FA-9677-F937296C5365

Q34526181-0AC62B44-C7F5-4306-BF50-0E2313FBB4F4

Q34526181-0B875680-34B2-4ABA-8331-2FAD8D63F8C8

Q34526181-1CB11118-E890-4C9B-8435-96BF5EFE698F

Q34526181-2F01EDC9-714C-4E85-BF97-E70E90138269

Q34526181-3024C54C-249E-44ED-8A5C-EA67D4D718C7

Q34526181-392F59A3-9572-447B-80B4-458859C565B9

Q34526181-3E873C92-194A-44D0-AB4D-69529204DED7

Q34526181-484C8082-E7D8-4919-AC7D-A832D580BA85

Q34526181-5E16902F-0713-4BB7-9B16-FE9C20574605

P304

Q34526181-DD5B9FDB-9F3D-449F-9CCD-37968733D39A

P31

Q34526181-3ED10302-A996-48DE-ABD9-4CE2E2534A58

P356

Q34526181-166A01B5-E937-4BB5-A14B-F3D1DF760625

P407

Q34526181-7C326623-C1EA-4DFE-AEDF-34B5DBE1F1C9

P433

Q34526181-41DC9D9B-7744-4631-BF3E-FB7D3CF420A0

P478

Q34526181-56A244F6-16F3-4AC2-841D-48A80523F220

P50

Q34526181-2361A616-9915-4BC0-9BD4-8C187689774A

Q34526181-2F7E4870-C5E9-40F9-84C2-127CFC55DA3E

Q34526181-8C14B681-3F65-49CD-B5CB-722E21290782

Q34526181-91BAFEF7-29BB-4715-8905-993F79E76675

P577

Q34526181-3C4891C2-FE48-4F45-B71C-2897B66A4964

P698

Q34526181-25A6F6E0-6B2E-4DF4-9190-D6900FD7A1E2

P921

Q34526181-432EA390-FF3B-4CC7-9E1B-71E07A3BC573

P932

Q34526181-2A7120C6-F9B7-4054-9107-C731E1C7050E

P356

SCITRANSLMED.AAF2362

P1433

Science Translational Medicine

P1476

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

@en

P2093

Anne M Fagan

http://www.w3.org/2001/XMLSchema#string

Ari Stern

http://www.w3.org/2001/XMLSchema#string

Beau M Ances

http://www.w3.org/2001/XMLSchema#string

Christopher Owen

http://www.w3.org/2001/XMLSchema#string

David M Holtzman

http://www.w3.org/2001/XMLSchema#string

Jason Hassenstab

http://www.w3.org/2001/XMLSchema#string

John C Morris

http://www.w3.org/2001/XMLSchema#string

Jon Christensen

http://www.w3.org/2001/XMLSchema#string

Matthew R Brier

http://www.w3.org/2001/XMLSchema#string

Nigel J Cairns

http://www.w3.org/2001/XMLSchema#string

P2860

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Neuropathological stageing of Alzheimer-related changes

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

Tau imaging: early progress and future directions

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Alzheimer's disease: the amyloid cascade hypothesis

The Clinical Dementia Rating (CDR): current version and scoring rules

Alzheimer's disease

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

P304

338ra66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAF2362

http://www.w3.org/2001/XMLSchema#string

P407

P433

338

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Karl Friedrichsen

Tammie L. Benzinger

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27169802

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

5267531

http://www.w3.org/2001/XMLSchema#string